Related Experiment Videos
A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants
A E Kopelman1, A A Moise, D Holbert
1East Carolina University School of Medicine, Pediatrics-Neonatology, Greenville, North Carolina 27858-4354, USA.
Insights
A single dose of dexamethasone for premature infants born before 28 weeks gestation improved breathing support and blood pressure in the first week. This treatment also reduced the need for indomethacin to treat patent ductus arteriosus.
Area of Science:
- Neonatal medicine
- Pediatric pharmacology
- Critical care
Background:
- Premature infants (<28 weeks gestation) often experience cardiopulmonary difficulties.
- Early interventions are crucial for improving outcomes in extremely preterm neonates.
- Intraventricular hemorrhage and patent ductus arteriosus are significant morbidities in this population.
Purpose of the Study:
- To evaluate the effect of a single early dose of dexamethasone on cardiopulmonary adaptation in infants <28 weeks' gestation.
- To assess the impact of early dexamethasone on the incidence of significant intraventricular hemorrhage.
- To analyze the influence on ventilator settings, blood pressure, and medication use.
Main Methods:
- Prospective, blinded, placebo-controlled randomized study.
- 70 infants <28 weeks gestation received either dexamethasone (0.2 mg/kg) or placebo within 2 hours of delivery.
- Interim analysis led to early study termination; focus shifted to early outcomes.
Main Results:
- Dexamethasone group showed more rapid ventilator weaning with lower intermittent mandatory ventilation rates and peak inspiratory pressures.
- Higher mean blood pressures were observed in the dexamethasone group within 12 hours, persisting through day 5.
- Significantly fewer infants in the dexamethasone group received indomethacin for patent ductus arteriosus (22% vs 47%).
Conclusions:
- Early administration of dexamethasone in extremely preterm infants improves respiratory support and hemodynamic stability.
- This intervention reduces the need for indomethacin treatment for patent ductus arteriosus.
- Further research may explore long-term effects and optimal dosing strategies.
Objectives:
To test the hypothesis that a single dose of dexamethasone given soon after delivery to infants <28 weeks' gestation leads to improved cardiopulmonary adaptation in the first week and lowers the risk of significant intraventricular hemorrhage.
Methods:
In a prospective, blinded, placebo-controlled study, we randomly assigned 70 infants <28 weeks' gestation who were born in the hospital to receive dexamethasone (0.2 mg/kg) (n = 37) or normal saline solution (n = 33) within 2 hours of delivery. After an interim analysis showed that the incidence of intraventricular hemorrhage was much lower than expected, enrollment was stopped and we limited our analysis to a comparison of ventilator settings, blood pressure, and pressor use during the first 7 days.
Results:
Clinical characteristics of the groups were comparable at study entry. Ventilator weaning occurred more rapidly in the patients who received dexamethasone: their intermittent mandatory ventilation rate was significantly lower on days 1 through 6, and their peak inspiratory pressure was lower on days 3 through 7 compared with the control group. Mean blood pressures were higher in the dexamethasone group within 12 hours and remained higher through day 5, but the use of pressors was not different. Fewer infants in the dexamethasone group received indomethacin to treat a patent ductus arteriosus (22% vs 47%, P <.03).
Conclusion:
Dexamethasone given within 2 hours of delivery to preterm infants <28 weeks' gestation resulted in lower ventilator settings and higher mean blood pressures during the first 7 days. Fewer infants required indomethacin to treat a patent ductus arteriosus.